Tech Center 1600 • Art Units: 1625
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18540582 | SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR | Final Rejection | Xenon Pharmaceuticals Inc. |
| 18266917 | USE OF MGLUR5 ANTAGONISTS FOR TREATING GAMBLING DISORDER | Non-Final OA | Yale University |
| 18308357 | METHOD OF TREATING, AMELIORATING AND/OR PREVENTING DEPRESSION | Non-Final OA | YALE UNIVERSITY |
| 18332751 | TREATING REFRACTIVE DISORDERS BY TARGETING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) SIGNALING PATHWAY | Non-Final OA | The Hong Kong Polytechnic University |
| 18649184 | COMPOUNDS AND USES THEREOF | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 17759806 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, MYODEGENERATIVE, AND LYSOSOMAL STORAGE DISORDERS | Final Rejection | GEORGETOWN UNIVERSITY |
| 18447057 | METHOD AGAINST SNAKE ENVENOMATION | Non-Final OA | National Tsing Hua University |
| 18654220 | METHODS SUITABLE FOR DISRUPTING A BIOFILM, AND/OR KILLING BACTERIA CONTAINED IN A BIOFILM | Final Rejection | Kenvue Brands LLC |
| 18039917 | AMILORIDE DERIVATIVES AND METHODS OF USING SAME FOR THE TREATMENT OF VIRAL INFECTIONS | Non-Final OA | Rutgers, The State University of New Jersey |
| 18254897 | COMPOUNDS HAVING INHIBITORY EFFECT ON MITOCHONDRIAL HYPERFISSION | Non-Final OA | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION |
| 18632522 | R-FADROZOLE FOR USE IN THE TREATMENT OF ALDOSTONERISM | Final Rejection | DAMIAN PHARMA AG |
| 18560953 | PURGE PROCESS FOR 5-(METHOXYCARBONYL)FURAN-2-CARBOXYLIC ACID (MCFC) | Non-Final OA | EASTMAN CHEMICAL COMPANY |
| 18560956 | MOTHER LIQUOR COMPOSITION GENERATED IN MCFC PROCESS | Non-Final OA | Eastman Chemical Company |
| 18576990 | Melafenoxate, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with neurodegenerative diseases such as Alzheimer's disease | Non-Final OA | NLS Pharmaceutics AG |
| 18565188 | METHODS FOR TREATING AUTISM SPECTRUM DISORDERS (ASD) | Non-Final OA | SK BIOPHARMACEUTICALS CO., LTD. |
| 18555388 | Methods For Treating Drug and Vaccine Induced Immune Thrombocytopenia by Administering Specific Compounds | Non-Final OA | Principia Biopharma Inc. |
| 18014932 | PENTACYCLIC TRITERPENOID GLYCOSIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES |
| 18552305 | PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION | Non-Final OA | ANAVEX LIFE SCENCES CORP. |
| 18256747 | COMPOUNDS FOR TREATING EYE DISEASES AND DISORDERS | Non-Final OA | Tel Hashomer Medical Research Infrastructure and Services Ltd. |
| 18264810 | TREATMENTS OF HEREDITARY ANGIOEDEMA | Non-Final OA | KALVISTA PHARMACEUTICALS LIMITED |
| 18263698 | USE OF THE AXL INHIBITOR SLC-391 AS ANTIVIRAL THERAPEUTIC AGENT | Non-Final OA | SignalChem Lifesciences Corporation |
| 18274896 | DMT SALTS AND THEIR USE TO TREAT BRAIN INJURY | Non-Final OA | ALGERNON PHARMACEUTICALS INC. |
| 18263191 | USE OF COMPOSITION CONTAINING CILOSTAZOL IN CEREBROVASCULAR DISEASES | Non-Final OA | NEURODAWN PHARMACEUTICAL CO., LTD. |
| 18016625 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | Non-Final OA | SANOFI PASTEUR |
| 18030336 | A METHOD FOR REDUCING ALLERGENS | Non-Final OA | AQDOT LIMITED |
| 17801219 | USE OF COMPOUND IN PREVENTION AND/OR TREATMENT OF PATHOGEN INFECTION IN ANIMALS | Final Rejection | FELICAMED BIOTECHNOLOGY CO., LTD. |
| 16938475 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Final Rejection | XENIOPRO GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy